$880 Million is the total value of Rhenman & Partners Asset Management AB's 86 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 22.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CI | Sell | CIGNA CORP NEW | $29,251,000 | +9.0% | 111,000 | -0.9% | 3.32% | +25.5% |
| LLY | Sell | LILLY ELI & CO | $29,181,000 | -17.5% | 90,000 | -27.1% | 3.32% | -5.0% |
| ABBV | Sell | ABBVIE INC | $29,100,000 | -7.9% | 190,000 | -2.6% | 3.31% | +6.0% |
| UNH | Sell | UNITED HEALTH GROUP INC | $28,763,000 | -2.8% | 56,000 | -3.4% | 3.27% | +12.0% |
| HZNP | Sell | HORIZON THERAPEUTICS PUB L | $25,946,000 | -26.6% | 325,299 | -3.1% | 2.95% | -15.4% |
| JAZZ | Sell | JAZZ PHARMACEUTICALS PLC | $24,962,000 | -11.9% | 160,000 | -12.1% | 2.84% | +1.5% |
| MCK | Sell | MCKESSON CORP | $20,551,000 | -29.3% | 63,000 | -33.7% | 2.34% | -18.6% |
| JNJ | Sell | JOHNSON & JOHNSON | $17,751,000 | -11.4% | 100,000 | -11.5% | 2.02% | +2.1% |
| MDT | Sell | MEDTRONIC PLC | $13,463,000 | -24.2% | 150,000 | -6.2% | 1.53% | -12.6% |
| HRMY | Sell | HARMONY BIOSCIENCES HLDGS IN | $12,680,000 | -2.8% | 260,000 | -3.1% | 1.44% | +11.9% |
| BMRN | Sell | BIOMARIN PHARMACEUTICAL INC | $11,602,000 | -31.6% | 140,000 | -36.4% | 1.32% | -21.3% |
| COO | Sell | COOPER COS INC | $11,585,000 | -39.7% | 37,000 | -19.6% | 1.32% | -30.6% |
| ALNY | Sell | ALNYLAM PHARMACEUTICALS INC | $10,939,000 | -48.5% | 75,000 | -42.3% | 1.24% | -40.6% |
| APLS | Sell | APELLIS PHARMACEUTICALS INC | $9,496,000 | -50.4% | 210,000 | -44.3% | 1.08% | -42.9% |
| NBIX | Sell | NEUROCRINE BIOSCIENCES INC | $9,261,000 | -5.9% | 95,000 | -9.5% | 1.05% | +8.3% |
| CYTK | Sell | CYTOKINETICS INC | $9,037,000 | -16.8% | 230,000 | -22.0% | 1.03% | -4.1% |
| PRVA | Sell | PRIVIA HEALTH GROUP INC | $8,736,000 | -17.8% | 300,000 | -24.5% | 0.99% | -5.2% |
| REGN | Sell | REGENERON PHARMACEUTICALS | $8,276,000 | -58.4% | 14,000 | -50.9% | 0.94% | -52.1% |
| XNCR | Sell | XENCOR INC | $8,211,000 | -10.4% | 300,000 | -12.7% | 0.93% | +3.1% |
| SGEN | Sell | SEAGEN INC | $7,999,000 | -9.0% | 45,208 | -25.9% | 0.91% | +4.8% |
| ITCI | Sell | INTRA-CELLULAR THERAPIES INC | $7,991,000 | -53.4% | 140,000 | -50.0% | 0.91% | -46.3% |
| ESPR | Sell | ESPERION THERAPEUTICS INC NE | $5,724,000 | +25.7% | 900,000 | -8.3% | 0.65% | +44.8% |
| IMGN | Sell | IMMUNOGEN INC | $5,400,000 | -20.4% | 1,200,000 | -15.8% | 0.61% | -8.2% |
| IMCR | Sell | IMMUNOCORE HLDGS PLCads | $5,223,000 | +2.5% | 140,000 | -17.9% | 0.59% | +17.9% |
| ALKS | Sell | ALKERMES PLC | $4,469,000 | -5.6% | 150,000 | -16.7% | 0.51% | +8.8% |
| EW | Sell | EDWARDS LIFESCIENCES CORP | $4,279,000 | -44.1% | 45,000 | -30.8% | 0.49% | -35.6% |
| ALGN | Sell | ALIGN TECHNOLOGY INC | $4,260,000 | -67.4% | 18,000 | -40.0% | 0.48% | -62.5% |
| AERI | Sell | AERIE PHARMACEUTICALS INC | $4,218,000 | -21.3% | 562,350 | -4.6% | 0.48% | -9.5% |
| NVCR | Sell | NOVOCURE LTD | $4,170,000 | -27.8% | 60,000 | -13.9% | 0.47% | -16.8% |
| GKOS | Sell | GLAUKOS CORP | $4,087,000 | -32.9% | 89,991 | -14.5% | 0.46% | -22.8% |
| SGMO | Sell | SANGAMO THERAPEUTICS INC | $2,898,000 | -34.5% | 700,000 | -8.1% | 0.33% | -24.5% |
| TDOC | Sell | TELADOC HEALTH INC | $2,823,000 | -57.5% | 85,000 | -7.6% | 0.32% | -51.0% |
| PGNY | Sell | PROGYNY INC | $2,615,000 | -49.1% | 90,000 | -10.0% | 0.30% | -41.4% |
| ISEE | Sell | IVERIC BIO INC | $2,405,000 | -45.0% | 250,000 | -3.8% | 0.27% | -36.8% |
| NKTR | Sell | NEKTAR THERAPEUTICS | $2,090,000 | -36.8% | 550,000 | -10.4% | 0.24% | -27.3% |
| PHR | Sell | PHREESIA INC | $1,876,000 | -39.2% | 75,000 | -35.9% | 0.21% | -29.9% |
| IONS | Sell | IONIS PHARMACEUTICALS INC | $1,851,000 | -29.6% | 50,000 | -29.6% | 0.21% | -18.9% |
| RIGL | Sell | RIGEL PHARMACEUTICALS INC | $1,384,000 | -63.8% | 1,225,081 | -4.1% | 0.16% | -58.4% |
| EPIX | Sell | ESSA PHARMA INC | $1,181,000 | -53.5% | 375,000 | -8.7% | 0.13% | -46.6% |
| ANNX | Exit | ANNEXON INC | $0 | – | -250,000 | -100.0% | -0.07% | – |
| PIRS | Exit | PIERIS PHARMACEUTICALS INC | $0 | – | -300,000 | -100.0% | -0.09% | – |
| OLMA | Exit | OLEMA PHARMACEUTICALS INC | $0 | – | -500,000 | -100.0% | -0.21% | – |
| MGNX | Exit | MACROGENICS INC | $0 | – | -287,081 | -100.0% | -0.25% | – |
| BIIB | Exit | BIOGEN INC | $0 | – | -15,000 | -100.0% | -0.31% | – |
| ACCD | Exit | ACCOLADE INC | $0 | – | -200,000 | -100.0% | -0.35% | – |
| OSH | Exit | OAK STR HEALTH INC | $0 | – | -150,000 | -100.0% | -0.40% | – |
| GDRX | Exit | GOODRX HLDGS INC | $0 | – | -235,000 | -100.0% | -0.45% | – |
| RCM | Exit | R1 RCM INC | $0 | – | -282,189 | -100.0% | -0.74% | – |
| CNC | Exit | CENTENE CORP DEL | $0 | – | -187,000 | -100.0% | -1.55% | – |
| BHVN | Exit | BIOHAVEN PHARMACTL HLDG CO L | $0 | – | -136,000 | -100.0% | -1.59% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITEDHEALTH GROUP INC | 40 | Q3 2023 | 4.0% |
| BIOMARIN PHARMACEUTICAL INC | 40 | Q3 2023 | 5.0% |
| ALKERMES PLC | 40 | Q3 2023 | 3.3% |
| LILLY ELI & CO | 39 | Q3 2023 | 5.8% |
| CVS HEALTH CORP | 39 | Q3 2023 | 3.5% |
| INTRA-CELLULAR THERAPIES INC | 39 | Q3 2023 | 2.4% |
| EDWARDS LIFESCIENCES CORP | 39 | Q3 2023 | 1.7% |
| VERTEX PHARMACEUTICALS INC | 38 | Q3 2023 | 4.3% |
| REVANCE THERAPEUTICS INC | 38 | Q3 2023 | 0.9% |
| ABBVIE INC | 37 | Q3 2023 | 4.4% |
View Rhenman & Partners Asset Management AB's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR/A | 2023-11-13 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Rhenman & Partners Asset Management AB's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.